Crossmark

Investigating Partially Discordant Results in Phase 3 Studies of Aducanumab

Crossref DOI link: https://doi.org/10.14283/jpad.2023.6

Published Print: 2023-04

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Mallinckrodt, C.

Tian, Y.

Aisen, P.S.

Barkhof, F.

Cohen, S.

Dent, G.

Hansson, O.

Harrison, K.

Iwatsubo, T.

Mummery, C.J.

Muralidharan, K.K.

Nestorov, I.

Nisenbaum, L.

Rajagovindan, R.

von Hehn, C.

van Dyck, C.H.

Vellas, B.

Wu, S.

Zhu, Y.

Sandrock, A.

Chen, T.

Budd Haeberlein, Samantha
License Information

Text and Data Mining valid from 2023-04-01

Text and Data Mining valid from 2023-04-01

Version of Record valid from 2023-01-12
More Information

This article is maintained by: Elsevier

Article Title: Investigating Partially Discordant Results in Phase 3 Studies of Aducanumab

Journal Title: The Journal of Prevention of Alzheimer's Disease

CrossRef DOI link to publisher maintained version: https://doi.org/10.14283/jpad.2023.6

Content Type: article

Copyright: Copyright © 2023 THE AUTHORS. Published by Elsevier Masson SAS on behalf of SERDI Publisher. Published by Elsevier Masson SAS